Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Front Endocrinol (Lausanne). 2021 May 24;12:689887. doi: 10.3389/fendo.2021.689887. eCollection 2021.
Syndrome of inappropriate antidiuresis (SIAD) can be a complication of hypothalamus-pituitary surgery. The use of tolvaptan in this setting is not well established, hence the primary aim of this study was to assess the sodium correction rates attained with tolvaptan compared with standard treatments (fluid restriction and/or hypertonic saline). Furthermore, we compared the length of hospital stay in the two treatment groups and investigated the occurrence of overcorrection and side effects including osmotic demyelination syndrome.
We retrospectively reviewed 308 transsphenoidal surgical procedures performed between 2011 and 2019 at our hospital. We selected adult patients who developed post-operative SIAD and recorded sodium monitoring, treatment modalities and outcomes. Correction rates were adjusted based on pre-treatment sodium levels.
Twenty-nine patients (9.4%) developed post-operative SIAD. Tolvaptan was administered to 14 patients (median dose 15 mg). Standard treatments were employed in 14 subjects (fluid restriction n=11, hypertonic saline n=1, fluid restriction and hypertonic saline n=2). Tolvaptan yielded higher adjusted sodium correction rates (12.0 mmolL/24h and 13.4 mmolL/48h) than standard treatments (1.8 mmolL/24h, p<0.001, and 4.5 mmolL/48h, p=0.004, tolvaptan). The correction rate exceeded 10 mmolL/24h or 18 mmolL/48h in 9/14 and 2/14 patients treated with tolvaptan, respectively, and in no patient who received standard treatments. No side effects including osmotic demyelination occurred. Tolvaptan was associated with a shorter hospital stay (1115 days, p=0.01).
Tolvaptan is more effective than fluid restriction (with or without hypertonic saline) and allows for a shortened hospital stay in patients with SIAD after transsphenoidal surgery. However, its dose and duration should be carefully tailored, and close monitoring is recommended to allow prompt detection of overcorrection.
抗利尿激素不适当分泌综合征(SIAD)可能是下丘脑-垂体手术的并发症。托伐普坦在这种情况下的应用尚未得到充分证实,因此本研究的主要目的是评估与标准治疗(液体限制和/或高渗盐水)相比,托伐普坦达到的钠校正率。此外,我们比较了两组治疗的住院时间,并研究了过度校正和包括渗透性脱髓鞘综合征在内的副作用的发生情况。
我们回顾性分析了 2011 年至 2019 年期间在我院进行的 308 例经蝶窦手术。我们选择了术后发生 SIAD 的成年患者,并记录了钠监测、治疗方式和结果。校正率根据治疗前的钠水平进行调整。
29 例(9.4%)患者术后发生 SIAD。14 例患者给予托伐普坦(中位剂量 15mg)。14 例患者采用标准治疗(液体限制 11 例,高渗盐水 1 例,液体限制和高渗盐水 2 例)。与标准治疗(液体限制:24 小时内 12.0mmol/L,48 小时内 13.4mmol/L,p<0.001;高渗盐水:24 小时内 4.5mmol/L,p=0.004)相比,托伐普坦的钠校正率更高(24 小时内 12.0mmol/L,48 小时内 13.4mmol/L,p<0.001)。托伐普坦治疗的 14 例患者中,9 例患者的校正率超过 10mmol/L/24h,2 例患者的校正率超过 18mmol/L/48h,而接受标准治疗的患者中无一人超过。没有发生包括渗透性脱髓鞘综合征在内的副作用。托伐普坦组的住院时间更短(1115 天,p=0.01)。
与液体限制(无论是否联合高渗盐水)相比,托伐普坦在经蝶窦手术后发生 SIAD 的患者中更有效,并可缩短住院时间。然而,应谨慎调整其剂量和持续时间,并建议密切监测,以尽快发现过度校正。